Item 1.01. Entry into a Material Definitive Agreement.

On December 11, 2012, in connection with the closing of the transaction contemplated by that certain credit agreement (the "Credit Agreement"), dated November 27, 2012, between Curis, Inc. ("Curis"), Curis Royalty LLC, a Delaware limited liability company and wholly-owned subsidiary of Curis ("Curis Royalty") and BioPharma Secured Debt Fund II Sub, S.à r.l., a Luxembourg limited liability company managed by Pharmakon Advisors ("BioPharma-II"), Curis entered into the following agreements previously reported on Curis' Current Report on Form 8-K filed with the Securities Exchange Commission on November 28, 2012, which is incorporated herein by reference:

• Purchase and Sale Agreement, dated as of December 11, 2012, between Curis and Curis Royalty;

• Consent and Payment Direction Letter Agreement, dated November 20, 2012 and effective as of December 11, 2012 between Curis, Curis Royalty and Genentech, Inc.; and

• Escrow Agreement, dated as of December 11, 2012 between Curis, Curis Royalty, BioPharma-II and Boston Private Bank and Trust Company.

Item 8.01. Other Events.

On December 12, 2012, Curis issued a press release announcing the closing of the transactions contemplated by the Credit Agreement. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto.

---